Abstract:Mammalian target of rapamycin (mTOR) regulates cell growth, cell differentiation and protein synthesis. Rapamycin, an inhibitor of mTOR, has been widely used as an immunosuppressant and anti-cancer drug. Recently, mTOR inhibitors have also been reported to be a potential anti-epileptic drug, which may be effective when used in young patients with genetic epilepsy. Thus, a suitable dose of rapamycin which can maintain the normal function of mTOR and has fewer side effects ideally should be identified. In the present study, we first detected changes in marker proteins of mTOR signaling pathway during development. Then we determined the dose of rapamycin by treating rats of 2 weeks of age with different doses of rapamycin for 3 days and detected its effect on mTOR pathway. Young rats were then treated with a suitable dose of rapamycin for 4 weeks and the effect of rapamycin on mTOR, development and immunity were investigated. We found that the expression of the marker proteins of mTOR pathway was changed during development in brain hippocampus and neocortex. After 3 days of treanent, 0.03 mg/kg rapamycin had no effect on phospho-S6, whereas 0.1, 0.3, 1.0 and 3.0 mg/kg rapamycin inhibited phospho-S6 in a dose-dependent manner. However, only 1.0 mg/kg and 3.0 mg/kg rapamycin inhibited phospho-S6 after 4 weeks treatment of rapamycin. Parallel to this result, rats treated with 0.1 and 0.3 mg/kg rapamycin had no obvious adverse effects, whereas rats treated with 1.0 and 3.0 mg/kg rapamycin showed significant decreases in body, spleen and thymus weight. Additionally, rats treated with 1.0 and 3.0 mg/kg rapamycin exhibited cognitive impairment and anxiety as evident by maze and open field experiments. Furthermore, the content of IL-1β, IL-2, IFN-γ, TNF-α in serum and cerebral cortex were significantly decreased in 1.0 and 3.0 mg/kg rapamycin-treated rats. The expression of DCX was also significantly decreased in 1.0 and 3.0 mg/kg rapamycin-treated rats. However, rats treated with 1.0 mg/ kg rapamycin exhibited fewer and milder side effects than those treated with 3.0 mg/kg. In summary, all these data suggest that there is not a rapamycin dose that can inhibit mTOR for epilepsy without causing any side effects, but 1 mg /kg may be the optimal dose for young rats for suppressing mTOR with relatively few side effects.

Peripheral tissular analysis of rapamycin's effect as a neuroprotective agent in vivo

Rapamycin Reduces Podocyte Apoptosis and is Involved in Autophagy and Mtor/ P70S6K/4EBP1 Signaling.

Rapamycin Protects The Mitochondria Against Oxidative Stress And Apoptosis In A Rat Model Of Parkinson'S Disease

Rapamycin Promotes Autophagy and Reduces Neural Tissue Damage and Locomotor Impairment after Spinal Cord Injury in Mice.

Rapamycin prevents early steps of the development of diabetic nephropathy in rats.

Protective Effect of Rapamycin against Mitochondrial Injury in an Aging Parkinson's Disease Mouse Model

Effect of Chronic Administration of Low Dose Rapamycin on Development and Immunity in Young Rats

Effects of rapamycin on behavior,oxidative stress status and mitochondria-related gene expression in rat model of Parkinson′s disease

Protective Effect of Rapamycin in Models of Retinal Degeneration.

Rapamycin Confers Neuroprotection Against Colistin-Induced Oxidative Stress, Mitochondria Dysfunction, and Apoptosis Through the Activation of Autophagy and Mtor/akt/creb Signaling Pathways.

The Post-Therapeutic Effect of Rapamycin in Mild Traumatic Brain-Injured Rats Ensuing in the Upregulation of Autophagy and Mitophagy.

Neuroprotection Through Rapamycin-Induced Activation of Autophagy and PI3K/Akt1/mTOR/CREB Signaling Against Amyloid-β-Induced Oxidative Stress, Synaptic/Neurotransmission Dysfunction, and Neurodegeneration in Adult Rats

Effect and Mechanism of Rapamycin on Cognitive Deficits in Animal Models of Alzheimer's Disease: A Systematic Review and Meta-analysis of Preclinical Studies

Rapamycin Enhances Mitophagy and Attenuates Apoptosis after Spinal Ischemia-Reperfusion Injury.

Rapamycin restores brain vasculature, metabolism, and blood-brain barrier in an inflammaging model

Rapamycin Alleviates Neuronal Injury and Modulates Microglial Activation After Cerebral Ischemia

Role of rapamycin in protection against cerebral ischemia-induced brain injury is related to neurogenesis in discrete brain regions in rat

The mTOR inhibitor Rapamycin protects from premature cellular senescence early after experimental kidney transplantation

Effects of low-dose rapamycin on lymphoid organs of mice prone and resistant to accelerated senescence

Rapamycin Inhibits Lipopolysaccharide-Induced Neuroinflammation in Vitro and in Vivo.

Rapamycin Induces Glucose Intolerance in Mice by Reducing Islet Mass, Insulin Content, and Insulin Sensitivity